Aligos Therapeutics, Inc. announced that the company is presenting several posters collectively highlighting data from its liver disease programs at the European Association for the Study of the Liver (EASL) Congress 2023, taking place in Vienna, Austria, June 21 - 24, 2023. Notably, the Company's late breaking poster (LBP-18) highlights promising emerging data from its ongoing Phase 1b study evaluating the oral capsid assembly modulator (CAM-E), ALG-000184. Specifically, a majority of HBeAg positive subjects dosed with 300 mg ALG-000184 + entecavir (ETV) for up to 36 weeks demonstrated time-dependent HBsAg reductions, with a maximum reduction of 2.0 log10 IU/mL observed in week 36.

Importantly, ALG-000184 continues to demonstrate a favorable safety and pharmacokinetic (PK) profile over these extended dosing durations. Additionally, the Company is presenting results from its ongoing Phase 1 study evaluating single ascending doses of ALG-125755, a GalNAc-conjugated small interfering RNA, in virologically suppressed subjects with chronic hepatitis B (CHB).